AP
Therapeutic Areas
Editas Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EDIT-401 | Hyperlipidemia & Atherosclerotic Cardiovascular Disease (ASCVD) | Preclinical |
| Undisclosed In Vivo Program | Sickle Cell Disease (SCD) / Beta thalassemia | Research |
| Collaborative Alpha-Beta T-cell Assets | Oncology | Various (Partner-led) |
| Collaborative Gamma-Delta T-cell Assets | Oncology | Various (Partner-led) |
Leadership Team at Editas Medicine
GO
Gilmore O’Neill
President and Chief Executive Officer
BB
Brieana Buckley
Senior Vice President, Development and Program Leadership
LC
Linda C. Burkly
Executive Vice President and Chief Scientific Officer
DG
Damien Grierson
Senior Vice President and General Counsel
FP
Frank Panaccio
Senior Vice President and Chief Business Officer
GW
Gregory Whitehead
Executive Vice President and Chief Technical and Quality Officer